ENMD-1198, with the CAS number 864668-87-1, is a synthetic compound that has garnered interest in the field of medicinal chemistry, particularly for its potential applications in cancer treatment. It is classified as a small molecule and is known to act as an inhibitor of specific kinases, which are enzymes that play a crucial role in various cellular processes, including cell division and growth. The compound exhibits a unique chemical structure that contributes to its biological activity, and it has been studied for its efficacy against certain types of tumors. ENMD-1198's mechanism of action involves the modulation of signaling pathways that are often dysregulated in cancer cells, making it a candidate for targeted therapy. Additionally, its pharmacokinetic properties, such as absorption, distribution, metabolism, and excretion, are essential for determining its therapeutic potential and safety profile. Ongoing research aims to further elucidate its effectiveness and optimize its use in clinical settings.

ENMD-1198

864668-87-1: ENMD-1198, with the CAS number 864668-87-1, is a synthetic compound that has garnered interest in the field of medicinal chemistry, particularly for its potential applications in cancer treatment. It is classified as a small molecule and is known to act as an inhibitor of specific kinases, which are enzymes that play a crucial role in various cellular processes, including cell division and growth. The compound exhibits a unique chemical structure that contributes to its biological activity, and it has been studied for its efficacy against certain types of tumors. ENMD-1198's mechanism of action involves the modulation of signaling pathways that are often dysregulated in cancer cells, making it a candidate for targeted therapy. Additionally, its pharmacokinetic properties, such as absorption, distribution, metabolism, and excretion, are essential for determining its therapeutic potential and safety profile. Ongoing research aims to further elucidate its effectiveness and optimize its use in clinical settings.

<p>ENMD-1198 is a novel analog of the naturally occurring molecule endostatin. It has been shown to inhibit endothelial cell proliferation in vitro, but it is not yet known whether this effect will translate to clinical efficacy. ENMD-1198 is currently undergoing phase I and II clinical trials for the treatment of breast cancer, prostate cancer, and other cancers. The drug has been shown to be well tolerated at doses up to 10 mg/kg, with no significant adverse reactions reported.</p>

<p>ENMD-119 is a 2-methoxyestradiol analog with antiproliferative and antiangiogenic activity. It is suitable for inhibiting HIF-1α and STAT3 in human HCC cells.</p>

CAS 864668-87-1

ENMD-1198

ENMD-1198

Ref: 3D-PJB66887

ENMD-1198

Ref: TM-T15234